What is the current Medical Radioactive Isotopes market size?

The Medical Radioactive Isotopes market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Medical Radioactive Isotopes market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Medical Radioactive Isotopes market?

Increasing demand for cancer treatment and diagnostic procedures drives the market.

What are the challenges facing the Medical Radioactive Isotopes market?

High production costs and stringent regulatory requirements pose significant challenges.

Which regions are leading the Medical Radioactive Isotopes market?

North America and Europe are the leading regions due to advanced healthcare infrastructure.

Who are the top companies in the Medical Radioactive Isotopes market?

Leading companies include GE Healthcare, Siemens, and Philips, offering innovative solutions.

What future opportunities exist in the Medical Radioactive Isotopes market?

Emerging economies and increasing adoption of nuclear medicine offer significant future opportunities.

How will technology impact the Medical Radioactive Isotopes market future outlook?

Advances in technology, such as PET scans, will drive growth and improve diagnostic accuracy.

What is the current regulatory landscape for the Medical Radioactive Isotopes market?

Stringent regulations, such as those from the FDA, ensure safety and efficacy of radioactive isotopes.

How will the Medical Radioactive Isotopes market size evolve in the next 5 years?

The market is expected to reach USD 1.8 billion by 2028, driven by increasing demand.

Medical Radioactive Isotopes Market Intelligence Report 2026 — Updated June 2026

Medical Radioactive Isotopes by Application (Nuclear Therapy, Equipment Radioactive Source, Diagnosis, Others), by Types (Tc-99m, Cobalt-60, Iodine Radioisotopes), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.9%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Medical Radioactive Isotopes Market Size | CAGR 7.9 Forecast 2033

Medical Radioactive Isotopes Market Intelligence Report 2026 — Updated June 2026

🏭 Chemicals & Materials🌍 Global

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.9%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 90

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.9%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medical Radioactive Isotopes Market Overview

The Medical Radioactive Isotopes market refers to the industry involved in the production and distribution of radioactive isotopes used in medical applications. As the Medical Radioactive Isotopes market size is expected to reach $12.5 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion driven by increasing demand for cancer treatments and diagnostic procedures. The scope of this market encompasses various types of radioactive isotopes, including technetium-99m, iodine-131, and lutetium-177, used in applications such as cancer therapy, diagnostics, and research.

Loading chart…

The Medical Radioactive Isotopes market is expected to grow at a compound annual growth rate (CAGR) of 10% from 2026 to 2033, driven by macro drivers such as an increasing prevalence of cancer, advancements in nuclear medicine, and rising demand for targeted therapies. Key forces shaping the industry include technology shifts towards more efficient and cost-effective production methods, regulatory requirements for safety and quality control, and competitive intensity among market players. The largest region in the Medical Radioactive Isotopes market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investments in healthcare infrastructure and rising awareness of nuclear medicine applications.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	23.52 million
Growth rate	CAGR of 7.9% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NRG; IRE; ANSTO; NTP Radioisotopes; China National Nuclear Corporation; Rosatom; Nordion; Eckert & Ziegler Strahlen; Polatom
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Medical Radioactive Isotopes market is poised for significant growth, driven by increasing demand for diagnostic and therapeutic applications. The Medical Radioactive Isotopes market size is expected to expand substantially, with a growth forecast that underscores the sector's potential.

Growth Drivers2 items

Advances in nuclear medicine and radiopharmaceuticals are driving the adoption of Medical Radioactive Isotopes, particularly in cancer treatment and diagnosis, thereby fueling the Medical Radioactive Isotopes market growth

Government initiatives and investments in medical research are further propelling the Medical Radioactive Isotopes market size, as these initiatives often lead to the development of new isotopes and applications

Restraints2 items

Stringent regulatory requirements and high production costs are significant restraints in the Medical Radioactive Isotopes market, as they can limit the availability and affordability of these isotopes

The short half-life of some Medical Radioactive Isotopes and the need for specialized storage and handling facilities also pose challenges, affecting the overall growth forecast of the Medical Radioactive Isotopes market

Opportunities2 items

Emerging technologies such as cyclotron-based production are creating new opportunities in the Medical Radioactive Isotopes market, enabling the production of a wider range of isotopes

Increasing demand from developing countries for Medical Radioactive Isotopes in diagnostic and therapeutic procedures presents a significant opportunity for market expansion, contributing to the growth forecast

Challenges2 items

The Medical Radioactive Isotopes market faces challenges related to supply chain disruptions, which can impact the availability of these critical materials, affecting the Medical Radioactive Isotopes market size

Ensuring the safe disposal of radioactive waste and mitigating the environmental impact of Medical Radioactive Isotopes production are ongoing challenges that the industry must address to maintain its growth trajectory and support the overall Medical Radioactive Isotopes market growth forecast

Market Segmentation

Loading chart…

The Medical Radioactive Isotopes market can be segmented based on Application, which includes subtypes such as diagnostic and therapeutic applications. Diagnostic applications account for a significant share of the market, driven by the increasing use of radioactive isotopes in imaging procedures such as positron emission tomography (PET) scans. Therapeutic applications, on the other hand, are growing in popularity due to their effectiveness in treating certain types of cancer.

Another key segment in the Medical Radioactive Isotopes segmentation is Types, which comprises subtypes such as radioiodine, molybdenum-99, and lutetium-177. Radioiodine is widely used for therapeutic purposes, while molybdenum-99 is used to produce other radioactive isotopes. Lutetium-177, a newer isotope, is gaining traction due to its potential in targeted cancer therapy. Understanding these segments is crucial for analyzing the market taxonomy and identifying growth opportunities in the Medical Radioactive Isotopes market.

Medical Radioactive Isotopes Segmentation Breakdown9 items

Application

Nuclear Therapy

Equipment Radioactive Source

Diagnosis

Others

Types

Tc-99m

Cobalt-60

Iodine Radioisotopes

Regional Insights

Loading chart…

The Medical Radioactive Isotopes market growth is anticipated to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is expected to be Asia Pacific, driven by increasing adoption of medical radioactive isotopes in the diagnosis and treatment of diseases.

Key drivers for North America include investments in research and development, a mature ecosystem, and favorable policies. In Europe, drivers include a high adoption rate of medical radioactive isotopes, a well-established infrastructure, and a large demographics base. Asia Pacific's growth is driven by increasing infrastructure development, rising adoption of medical radioactive isotopes, and government investments in the healthcare sector.

Latin America's growth is driven by increasing demographics and adoption of medical radioactive isotopes, while the Middle East & Africa region is driven by government policies and investments in the healthcare sector. The regional forecast indicates that these regions will contribute significantly to the global Medical Radioactive Isotopes market growth, with Asia Pacific being the fastest-growing region.

Competitive Landscape

The Medical Radioactive Isotopes market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Medical Radioactive Isotopes competitive landscape is characterized by high competition, with key players employing various strategies to differentiate themselves. Pricing and distribution are critical levers, while product innovation and certifications also play a significant role in shaping the market.

Companies in the Medical Radioactive Isotopes market are adopting strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. However, they face challenges like margin pressure, compliance costs, commoditization, and supply chain risks. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. The following companies are focusing on specific strategies to gain a competitive edge:

NRG: regional expansion

IRE: vertical integration

ANSTO: innovation pipeline

NTP Radioisotopes: local manufacturing

China National Nuclear Corporation: premium pricing

Rosatom: OEM tie-ups

Key Medical Radioactive Isotopes Companies9 items

NRG

IRE

ANSTO

NTP Radioisotopes

China National Nuclear Corporation

Rosatom

Nordion

Eckert & Ziegler Strahlen

Polatom

Market Ecosystem

The Medical Radioactive Isotopes ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured through the development, production, and distribution of radioactive isotopes for medical applications, with each participant playing a distinct role in the value chain analysis.

Raw material suppliers — providing essential materials

OEMs / manufacturers — producing radioactive isotopes

Technology providers — developing production technologies

System integrators / EPCs — designing and building production facilities

Distributors / channel partners — delivering isotopes to healthcare providers

Regulators/standards bodies — overseeing safety and efficacy standards

End users / buyers — utilizing isotopes for diagnostic and therapeutic purposes

In the Medical Radioactive Isotopes ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through stringent safety and efficacy standards. Dependency risks arise from input constraints, such as limited raw material availability, and approvals from regulatory authorities. Switching costs and partnerships are also critical, as companies may be locked into specific supply chains or collaborations, and interoperability requirements can affect the compatibility of equipment and technologies. The ecosystem's dynamics can differ by region, with varying regulatory frameworks and market demands impacting the production, distribution, and use of medical radioactive isotopes.

Recent Industry Insights

The Medical Radioactive Isotopes industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships between leading players have focused on enhancing research and development capabilities, driving innovation in the field. Notable mergers and acquisitions have also taken place, aiming to expand product portfolios and strengthen market presence. Furthermore, several companies have launched new products and technologies, including advanced diagnostic and therapeutic isotopes, to cater to the growing demand for precise and effective treatments.

Additionally, regulatory changes have been implemented to ensure the safe use and handling of medical radioactive isotopes. There has been a shift in consumer and enterprise trends, with an increasing emphasis on personalized medicine and targeted therapies. Funding rounds and expansions have also been observed, with investors showing keen interest in the potential of medical radioactive isotopes to revolutionize healthcare outcomes.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Medical Radioactive Isotopes market outlook. The market attractiveness is moderate, driven by increasing demand for cancer treatments and diagnostic procedures. Competitive intensity is high, with key players investing in research and development to improve their market share. The long-term outlook is positive, with opportunities for growth in emerging markets and innovation in radioisotope production.

The innovation landscape is rapidly evolving, with a focus on sustainable production methods and new applications. However, the demand–supply balance is a key risk factor, with shortages of certain isotopes affecting the market. Other risk factors include regulatory changes and supply chain disruptions. Overall, the Medical Radioactive Isotopes market is expected to experience steady growth, driven by increasing demand and innovation in the industry.

11 items

1. Executive Summary

2. Medical Radioactive Isotopes Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medical Radioactive Isotopes Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Medical Radioactive Isotopes Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Nuclear Therapy

6.1.2. Equipment Radioactive Source

6.1.3. Diagnosis

6.1.4. Others

6.2. Global Medical Radioactive Isotopes Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Tc-99m

6.2.2. Cobalt-60

6.2.3. Iodine Radioisotopes

6.3. Global Medical Radioactive Isotopes Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Medical Radioactive Isotopes Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medical Radioactive Isotopes Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Medical Radioactive Isotopes Market Competition by Key Manufacturers

8.1. Global Medical Radioactive Isotopes Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Medical Radioactive Isotopes: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. NRG

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IRE

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. ANSTO

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. NTP Radioisotopes

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. China National Nuclear Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Rosatom

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Nordion

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eckert & Ziegler Strahlen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Polatom

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medical Radioactive Isotopes Market

Figure 4: Global Medical Radioactive Isotopes Market: Drivers

Figure 5: Global Medical Radioactive Isotopes Market: Challenges

Figure 6: Global Medical Radioactive Isotopes Market: Trends

Figure 7: Global Medical Radioactive Isotopes Market: Opportunity

Figure 8: Global Medical Radioactive Isotopes Market: Restraint

Figure 9: Global Medical Radioactive Isotopes Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Medical Radioactive Isotopes Market Value (USD Million) By Region

Figure 15: Global Medical Radioactive Isotopes Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Medical Radioactive Isotopes Market Value (USD Million) By Region

Figure 23: Global Medical Radioactive Isotopes Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Medical Radioactive Isotopes Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Medical Radioactive Isotopes Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Medical Radioactive Isotopes Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Medical Radioactive Isotopes Market Value (USD Million) By Region

Table 10: Global Medical Radioactive Isotopes Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Medical Radioactive Isotopes Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Medical Radioactive Isotopes Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Medical Radioactive Isotopes Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: NRG Basic Information And Sales Area

Table 31: NRG. Products Portfolio

Table 32: IRE Basic Information And Sales Area

Table 33: IRE. Products Portfolio

Table 34: ANSTO Basic Information And Sales Area

Table 35: ANSTO. Products Portfolio

Table 36: NTP Radioisotopes Basic Information And Sales Area

Table 37: NTP Radioisotopes. Products Portfolio

Table 38: China National Nuclear Corporation Basic Information And Sales Area

Table 39: China National Nuclear Corporation. Products Portfolio

Table 40: Rosatom Basic Information And Sales Area

Table 41: Rosatom. Products Portfolio

Table 42: Nordion Basic Information And Sales Area

Table 43: Nordion. Products Portfolio

Table 44: Eckert & Ziegler Strahlen Basic Information And Sales Area

Table 45: Eckert & Ziegler Strahlen. Products Portfolio

Table 46: Polatom Basic Information And Sales Area

Table 47: Polatom. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Medical Radioactive Isotopes Market Value (USD Million) By Region

Table 53: Global Medical Radioactive Isotopes Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Medical Radioactive Isotopes Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	23.52 million
Growth rate	CAGR of 7.9% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	NRG; IRE; ANSTO; NTP Radioisotopes; China National Nuclear Corporation; Rosatom; Nordion; Eckert & Ziegler Strahlen; Polatom
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options